Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of VI-0521 (Qsymia) on GFR in Overweight/Obese Subjects
NCT02229214Phase 4Completed
- Sponsor
- VIVUS
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity and Overweight comparing VI-0521 (Qsymia) with Placebo (2 arms). Primary endpoints: Change in Glomerular Filtration Rate as Measured by Iohexol Clearance and Change in Glomerular Filtration Rate as Measured by Iohexol Clearance From Baseline to 28 Days After End of Treatment. Started Aug 2014; status: completed.
02
Drugs
phentermine + topiramate
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02229214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229214.